IL313654A - Combination of α2-adrenoceptor subtype c (alpha-2c) antagonists with a muscarinic receptor antagonist for the treatment of sleep apnea - Google Patents
Combination of α2-adrenoceptor subtype c (alpha-2c) antagonists with a muscarinic receptor antagonist for the treatment of sleep apneaInfo
- Publication number
- IL313654A IL313654A IL313654A IL31365424A IL313654A IL 313654 A IL313654 A IL 313654A IL 313654 A IL313654 A IL 313654A IL 31365424 A IL31365424 A IL 31365424A IL 313654 A IL313654 A IL 313654A
- Authority
- IL
- Israel
- Prior art keywords
- antagonists
- alpha
- treatment
- combination
- receptor antagonist
- Prior art date
Links
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 title 1
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 title 1
- 102000015006 alpha2-adrenergic receptor activity proteins Human genes 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 239000003149 muscarinic antagonist Substances 0.000 title 1
- 201000002859 sleep apnea Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21216889 | 2021-12-22 | ||
| PCT/EP2022/086928 WO2023118098A1 (en) | 2021-12-22 | 2022-12-20 | COMBINATION OF AN α2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS WITH A MUSCARINIC RECEPTOR ANTAGONIST FOR THE TREATMENT OF SLEEP APNEA |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL313654A true IL313654A (en) | 2024-08-01 |
Family
ID=79021054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL313654A IL313654A (en) | 2021-12-22 | 2022-12-20 | Combination of α2-adrenoceptor subtype c (alpha-2c) antagonists with a muscarinic receptor antagonist for the treatment of sleep apnea |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250057828A1 (https=) |
| EP (1) | EP4452245A1 (https=) |
| JP (1) | JP2025500346A (https=) |
| KR (1) | KR20240127392A (https=) |
| CN (1) | CN118434414A (https=) |
| AU (1) | AU2022422053A1 (https=) |
| CA (1) | CA3259602A1 (https=) |
| IL (1) | IL313654A (https=) |
| MX (1) | MX2024007767A (https=) |
| TW (1) | TW202342011A (https=) |
| WO (1) | WO2023118098A1 (https=) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3966781A (en) | 1970-12-17 | 1976-06-29 | Merck Sharp & Dohme (I.A.) Corporation | Deuteration of functional group-containing hydrocarbons |
| HRP20041026A2 (en) | 2002-04-03 | 2005-06-30 | Orion Corporation | Polycyclic compounds as potent alpha2-adrenoceptor antagonists |
| US8791162B2 (en) | 2011-02-14 | 2014-07-29 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| WO2017031319A1 (en) | 2015-08-18 | 2017-02-23 | Massachusetts Institute Of Technology | Noradrenergic drug treatment of obstructive sleep apnea |
| GEAP202416602A (en) | 2017-04-28 | 2024-10-10 | Brigham & Womens Hospital Inc | Methods and compositions for treating sleep apnea |
| KR102874891B1 (ko) | 2018-01-30 | 2025-10-21 | 애프니메드, 인코포레이티드 (델라웨어) | 수면 무호흡증을 치료하기 위한 방법 및 조성물 |
| US20210338662A1 (en) * | 2018-09-25 | 2021-11-04 | Bayer Aktiengeselischaft | Alpha-2-adrenoceptor subtype c (alpha-2c) antagonists for the treatment of sleep apnea |
| CA3139298A1 (en) | 2019-05-09 | 2020-11-12 | Bayer Aktiengesellschaft | Combination of an a2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea |
| TW202108139A (zh) | 2019-05-09 | 2021-03-01 | 德商拜耳廠股份有限公司 | 用於治療睡眠呼吸中止之α２—腎上腺素受體亞型Ｃ（α—２Ｃ）拮抗劑與ＴＡＳＫ１／３通道阻斷劑之組合 |
| EP3965763A1 (en) * | 2019-05-09 | 2022-03-16 | Bayer Aktiengesellschaft | Arylquinoziline derivatives as alpha2-adrenoceptor subtype c (alpha-2c) antagonists for the treatment of sleep apnea |
| PE20221025A1 (es) | 2019-11-06 | 2022-06-16 | Bayer Ag | Inhibidores de los receptores a2c adrenergicos |
| WO2022008426A1 (en) * | 2020-07-06 | 2022-01-13 | Bayer Aktiengesellschaft | Combination of an alpha2-adrenoceptor subtype c (alpha-2c) antagonist with a task1/3 channel blocker for the treatment of sleep apnea |
-
2022
- 2022-12-20 CA CA3259602A patent/CA3259602A1/en active Pending
- 2022-12-20 WO PCT/EP2022/086928 patent/WO2023118098A1/en not_active Ceased
- 2022-12-20 MX MX2024007767A patent/MX2024007767A/es unknown
- 2022-12-20 US US18/722,233 patent/US20250057828A1/en active Pending
- 2022-12-20 KR KR1020247024052A patent/KR20240127392A/ko active Pending
- 2022-12-20 JP JP2024537380A patent/JP2025500346A/ja active Pending
- 2022-12-20 IL IL313654A patent/IL313654A/en unknown
- 2022-12-20 TW TW111148913A patent/TW202342011A/zh unknown
- 2022-12-20 EP EP22840695.5A patent/EP4452245A1/en active Pending
- 2022-12-20 AU AU2022422053A patent/AU2022422053A1/en active Pending
- 2022-12-20 CN CN202280085160.3A patent/CN118434414A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240127392A (ko) | 2024-08-22 |
| CA3259602A1 (en) | 2023-06-29 |
| CN118434414A (zh) | 2024-08-02 |
| WO2023118098A1 (en) | 2023-06-29 |
| TW202342011A (zh) | 2023-11-01 |
| AU2022422053A1 (en) | 2024-07-11 |
| US20250057828A1 (en) | 2025-02-20 |
| EP4452245A1 (en) | 2024-10-30 |
| JP2025500346A (ja) | 2025-01-09 |
| MX2024007767A (es) | 2024-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2024028I2 (el) | Ενα διφαινυλοσουλφοναμιδιο ανταγωνιστης του υποδοχεα της ενδοθηλινης και της αγγειοτενσινης ii για τη θεραπεια της σπειραματοσκληρυνσης | |
| GEP20227387B (en) | Methods and compositions for treating sleep apnea | |
| IL208895A0 (en) | Nmda receptor antagonists for the treatment of neuropsychiatric disorders | |
| IL281645A (en) | Alpha2-adrenoceptor subtype 2 antagonists (ALPHA-2C) for the treatment of sleep apnea | |
| MY169479A (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| IL207001A (en) | Stable parenteral dosage form containing at least one dopamine agonist and the use of the dosage form to produce a drug | |
| EP2496249A4 (en) | GLP-1 RECEPTOR AGONIST COMPOUNDS FOR OBSTRUCTIVE SLEEP APNEA | |
| IL210404A0 (en) | Combination of a c- met antagonist and an aminoheteroaryl compound for the treatment of cancer | |
| UA96573C2 (ru) | Антагонисты кинина для лечения дисфункции мочевого пузыря | |
| JO3442B1 (ar) | مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5) | |
| CL2007003483A1 (es) | Compuestos derivados de indol-2-il-carbonil-espiro-piperidina, antagonistas del receptor de la v1a; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de hipertension, dismeno | |
| LT3456340T (lt) | Glp-1 receptoriaus antagonistas, skirtas įgimto hiperinsulinizmo gydymui | |
| MX2024013184A (es) | Metodos y composiciones para tratar apnea del sue?o | |
| NZ746118A (en) | A2a antagonists as cognition and motor function enhancers | |
| PL1863476T3 (pl) | Skojarzenie środków antycholinergicznych i antagonistów receptora leukotrienowego do leczenia chorób układu oddechowego | |
| ZA201008538B (en) | Treating psychological conditions using muscarinic receptor m1 antagonists | |
| IL299652A (en) | Combination of an alpha 2-adrenoceptor subtype C antagonist (ALPHA-2C) with a TASK1/3 channel blocker for the treatment of sleep apnea | |
| IL313654A (en) | Combination of α2-adrenoceptor subtype c (alpha-2c) antagonists with a muscarinic receptor antagonist for the treatment of sleep apnea | |
| CL2007003482A1 (es) | Compuestos derivados de 2-indol-2-il-carbonil-espiro-piperidina, antagonistas del receptor de la v1a; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de la ansiedad, trasto | |
| EA201291274A1 (ru) | Применение антагонистов аденозиновых рецепторов aдля лечения легочной гипертензии | |
| IL313647A (en) | Combination of a task1/3 channel blocker with a p2x3 receptor antagonist for the treatment of sleep apnea | |
| PH12014501390A1 (en) | Novel therapeutic use of p75 receptor antagonists | |
| IL213540A0 (en) | Selective histamine h4 receptor antagonists for the treatment of vestibular disorders | |
| IL313646A (en) | Combination of an α2-adrenoceptor subtype c (alpha-2c) antagonist with a norepinephrine reuptake inhibitor for the treatment of sleep apnea | |
| IL313652A (en) | Combination of a TASK1/3 channel blocker with a muscarinic receptor antagonist for the treatment of sleep apnea |